Refine
Is part of the Bibliography
- yes (2305) (remove)
Year of publication
Document Type
- Journal article (1422)
- Doctoral Thesis (798)
- Conference Proceeding (26)
- Book article / Book chapter (18)
- Review (16)
- Preprint (13)
- Book (5)
- Report (3)
- Master Thesis (2)
- Other (1)
Language
- English (1926)
- German (377)
- Multiple languages (2)
Keywords
- Biochemie (81)
- Taufliege (69)
- Drosophila (51)
- Physiologische Chemie (50)
- Genexpression (36)
- Biologie (34)
- Drosophila melanogaster (33)
- evolution (30)
- Biene (29)
- Maus (29)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (2305) (remove)
Sonstige beteiligte Institutionen
- Institut für Tierökologie und Tropenbiologie (2)
- Mildred-Scheel-Nachwuchszentrum (2)
- Ökologische Station Fabrikschleichach (2)
- Albert-Ludwigs-Universität Freiburg (1)
- Boehringer Ingelheim Pharma GmbH & Co. KG (1)
- Boston Children's Hospital (1)
- Center for Computational and Theoretical Biology (CCTB), Universität Würzburg (1)
- Chemical Biology Laboratory, National Cancer Institue, Frederick (USA) (1)
- Core Unit Systemmedizin (1)
- DNA Analytics Core Facility, Biocenter, University of Wuerzburg, Wuerzburg, Germany (1)
ResearcherID
- D-1221-2009 (1)
- J-8841-2015 (1)
- N-2030-2015 (1)
Porenbildende Zytolysine stellen wichtige Virulenzfaktoren von vielen pathogenen Bakterien dar. In Escherichia coli-Stämmen wurden bisher drei verschiedene porenbildende Zytolysine identifiziert, nämlich das alpha-Hämolysin (HlyA), das EHEC-Hämolysin (EHEC-HlyA, Ehx) und das latente Hämolysin ClyA. Alpha-Hämolysin und EHEC-Hämolysin, die beide zur Familie der RTX-Toxine gehören, werden häufig von uropathogenen bzw. enterohämorrhagischen E. coli-Stämmen gebildet. Verschiedene Untersuchungen haben gezeigt, daß das alpha-Hämolysin maßgeblich an der Pathogenität von uropathogenen E. coli-Stämmen beteiligt ist. Das Hämolysin ClyA, ein Protein von 34 kDa das keine Homologien zu den RTX-Toxinen aufweist, wurde zuerst im Laborstamm E. coli K-12 identifiziert, wo es unter normalen in vitro-Kulturbedingungen nur in sehr geringem Ausmaß exprimiert wird. Ein funktionales clyA-Gen wurde kürzlich aber auch in verschiedenen pathogenen E. coli-Stämmen, u. a. in enteroinvasiven E. coli (EIEC)-Stämmen, gefunden. Bislang ist jedoch unbekannt, ob ClyA eine Rolle in der Virulenz von pathogenen E. coli-Stämmen spielt. Die vorliegende Arbeit sollte deshalb zur Aufklärung der in vivo-Funktion von ClyA in E. coli beitragen. Im Mittelpunkt des Interesses stand dabei die Frage nach der Bedeutung von ClyA für EIEC-Stämme, die zur fakultativ intrazellulären Lebensweise befähigt sind. Ausgewählte wildtypische EIEC-Stämme (EIEC 12860, EIEC 4608-58) zeigten von sich aus bzw. bei Überexpression des Transkriptionsregulators SlyA phänotypisch sichtbare hämolytische Aktivität, während in vitro konstruierte isogene clyA-"knock-out"-Mutanten dieser Stämme stets nichthämolytisch waren. Daraus konnte geschlossen werden, daß die wildtypischen EIEC-Stämme in der Lage sind, ClyA in signifikanten Mengen zu exprimieren. Vergleichende Infektionsstudien, die mit dem EIEC-Stamm 4608-58 und der entsprechenden clyA-Mutante unter Verwendung von J774-Makrophagen durchgeführt wurden, ergaben außerdem, daß ClyA wesentlich zur Zytotoxizität des wildtypischen EIEC-Stamms beiträgt. Eine spezielle Bedeutung von ClyA für die fakultativ intrazelluläre Lebensweise von EIECs konnte mit diesen Versuchen allerdings nicht nachgewiesen werden. Frühere Untersuchungen hatten gezeigt, daß im Fall des fakultativ intrazellulären Bakteriums Listeria monocytogenes ein porenbildendes Toxin, Listeriolysin O (LLO), nach der Invasion in phagozytische Zellen die Befreiung der Bakterien aus dem Phagosom ermöglicht. Es stellte sich deshalb die Frage, ob ClyA bei EIECs möglicherweise eine ähnliche Rolle spielt. Um dies herauszufinden, wurde in der vorliegenden Arbeit untersucht, inwieweit ClyA von E. coli in der Lage ist, LLO in L. monocytogenes funktional zu ersetzen. Hierzu wurden L. monocytogenes-Mutanten, die aufgrund von chromosomalen Deletionen nicht in der Lage waren, LLO zu produzieren, mit verschiedenen Plasmiden komplementiert, welche clyA bzw. clyA-Derivate unter der Kontrolle der Promotorregion des LLO-Gens (hly) enthielten. Einige dieser komplementierten Stämme exprimierten und sezernierten tatsächlich das ClyA-Protein und zeigten dementsprechend auch einen hämolytischen Phänotyp. Dieselben Stämme waren jedoch bei Infektionen in J774-Zellen nicht in der Lage, sich intrazellulär signifikant zu vermehren, obwohl teilweise eine Befreiung der Bakterien aus dem Phagosom zu beobachten war. Diese Daten zeigten, daß das ClyA-Protein von E. coli das Listeriolysin O von L. monocytogenes nicht funktional ersetzen kann. Eine mögliche Funktion von ClyA als Phagosomenöffner in EIECs kann aufgrund der vorliegenden Ergebnisse jedoch nicht ausgeschlossen werden.
Die endogene Präsentation von intrazellulären Antigenen auf Major-Histokompatibilitätskomplex Klasse-II (MHC-II) -Molekülen ist von entscheidender Bedeutung für eine Reihe von immunologischen Prozessen. Die mechanistischen Grundlagen dieses Präsentationsweges sind aber noch weitgehend unverstanden. Ziel dieser Arbeit war es, einen Beitrag zum molekularen Verständnis der Abläufe zu leisten, die an der endogenen Präsentation nukleärer Antigene auf MHC-II-Molekülen beteiligt sind. Dazu sollte am Beispiel des nukleär lokalisierten Modellantigens Neomycin-Phosphotransferase II (NucNeoR) sowie des viralen Kernantigens Epstein-Barr-virus nuclear antigen 3C (EBNA3C) und entsprechender antigenspezifischer MHC-II-restringierter CD4+ T-Zellen die verantwortlichen Präsentationswege in professionell und nicht-professionell antigenpräsentierenden Zellen untersucht werden. In beiden Zellsystemen wurde NucNeoR über einen endogenen Präsentationsweg und nicht über die Freisetzung und Wiederaufnahme als exogenes Protein auf MHC-II-Molekülen präsentiert. Durch die Verwendung chemischer Inhibitoren konnte eine Beteiligung der Autophagie an der endogenen Antigenpräsentation nachgewiesen werden. Da Autophagie ausschließlich im Zytoplasma stattfindet, wurde nach möglichen Eintrittspforten für nukleäre Proteine in diesen Abbauweg gesucht. Für die Autophagie-abhängige Präsentation von NucNeoR war weder ein CRM1-vermittelter aktiver Export des Antigens aus dem Kern ins Zytoplasma, noch eine Auflösung der Kernmembran im Rahmen der Zellteilung und der dadurch bedingten Durchmischung nukleärer und zytoplasmatischer Bestandteile notwendig. Mit Hilfe eines konditionalen Antigenexpressionsystems und der Auftrennung antigenexprimierender Zellen nach Zellzyklusphasen konnte eine verstärkte Antigenpräsentation in der G1/0-Phase nachgewiesen werden, die mit fortschreitendem Zellzyklus immer mehr abnahm. Die Antigenpräsentation korrelierte dabei mit der ebenfalls im Laufe des Zellzyklus abnehmenden Transkriptions- bzw. Translationsrate des Antigens, aber nicht mit der absoluten Menge an Antigen in den Zellen. Bei abgeschalteter Antigentranskription dagegen korrelierte die Antigenpräsentation mit der MHC-II-Oberflächenexpression, die von der G1/0- bis hin zur G2/M-Phase kontinuierlich zunahm. Eine ähnliche Korrelation von Antigentranskription/ Antigentranslation und Autophagie-abhängiger Antigenpräsentation wurde auch für EBNA3C und die zytoplasmatisch lokalisierte NeoR-Variante beobachtet. Diese Ergebnisse identifizieren die Autophagie-abhängige Präsentation neusynthetisierter Proteine als den verantwortlichen molekularen Mechanismus für die endogene Präsentation der untersuchten nukleären Antigene auf MHC-II-Molekülen. Durch die Kopplung von Translation und autophagischem Abbau erlangen Proteine unabhängig von ihrer subzellulären Lokalisation Zugang zu diesem Präsentationsweg und erweitern so das Spektrum der intrazellulären Antigene, die einer CD4+ T-Zellüberwachung unterliegen.
Das maligne Melanom ist ein Hauttumor mit steigender Inzidenz und hohen Mortalitätsraten. Da die molekularbiologischen Ereignisse, die der Melanomentwicklung zugrundeliegen, nur unzureichend bekannt sind, gibt es kaum spezifische Therapieansätze. Zur Untersuchung der Melanomentwicklung eignet sich das Xiphophorus-Modell. In diesem System ist die Anwesenheit der RTK Xmrk ausreichend, um durch Aktivierung proliferativer und entdifferenzierender Signalwege und Apoptoseinhibition Melanome zu verursachen. Im Rahmen der vorliegenden Arbeit konnte gezeigt werden, dass Xmrk auch die Migration der Melanozytenzellinie Melan a-Hm induzieren kann. Die Migration der durch Xmrk transformierten Zellen ist amöboid und unabhängig von MAPK- und PI3K-Signalwegen. Eine Funktion bei der Migration haben jedoch die Kinasen FAK und Fyn. Sie bilden möglicherweise einen Proteinkomplex, der für FAK und Src aus zahlreichen anderen Systemen bekannt ist und als Signalplattform für die Zellmigration fungiert. Diese Erkenntnisse können dazu beitragen, das Xiphophorus-Modell weiterzuentwickeln und die Grundlagen der Melanomgenese besser zu verstehen.
Die Bedeutung der genomischen Instabilität in humanen melanocytischen Läsionen ist Gegenstand vieler dermatologischer Studien und bis heute ungeklärt. Ist die Mikrosatelliteninstabilität bloße Begleiterscheinung der unkontrolliert proliferierenden Tumorzellen oder wird ihr ein pathogenetischer Mechanismus zuteil? In Fischen der Gattung Xiphophorus können durch klassische Kreuzungsexperimente melanocytische Läsionen verschiedener Malignitätsgrade induziert werden. Diese Läsionen sind auf Grund ihres genetisch kontrollierten Hintergrundes eindeutig definiert und reproduzierbar - und damit im Vorteil gegenüber der unsicheren Klassifikation humaner Hautläsionen. In der vorliegenden Arbeit wurde hauptsächlich der Frage nachgegangen, ob MIN+ ein obligates molekulares Ereignis für die Progression von Melanomen bis zum terminalen Stadium darstellt. Dieser Fragestellung wurde unter Verwendung PCR-basierter Mikrosatellitenanalysen sowie Multilocus DNA-Fingerprint Analysen nachgegangen. 23 Tumoren unterschiedlicher Malignität wurden im Vergleich zum tumorfreien Normalgewebe desselben Fisches an 12 Genloci unbekannter chromosomaler Lokalisation auf Mikrosatelliteninstabilität untersucht. Es wurde insgesamt eine Zahl von 263 informativen Loci erzielt, von denen sich nur 20 ( = 7.6%) als instabil erwiesen. Mittels der Multilocus-Fingerprint Analysen wurden 8 Melanome und deren korrespondiere Normalgewebe mit drei Sonden hybridisiert. Nur einer von 12 analysierbaren MLFPs zeigte eine genetische Aberration in Form einer Deletion einer einzelnen Bande im Tumorgewebe. Mit diesem Ergebnis wurde das in der Mikrosatellitenanalyse erhaltene Resultat einer nicht signifikanten Mikrosatelliteninstabilität im Xiphophorus-Melanom-Modell System bestätigt. Zusammenfassend kann gesagt werden, daß die Abwesenheit eines MIN+-Phänotypen in den Melanomen von Xiphophorus darauf hinweist, daß der Erwerb von MIN weder ein notwendiges Kriterium für die Initiation eines Tumors noch für seine Progression darstellt. Ein anderer Pfad der Tumorinitiation ist die direkte Schädigung oder der Verlust von Tumorsuppressorgenen, von in Mismatch Repair involvierten Genen oder durch die Transformation von Proto-Onkogenen zu Onkogenen. In dieser Arbeit wurde die Expression von drei Genen, die in der Regulation des Zellzyklus Schlüsselrollen spielen (rb, p53, cdkn2a), sowie einer Komponente des MMR-Systems (MSH2) auf RNA-Ebene untersucht. Ihre Expressionsstärke wurde in folgenden Geweben miteinander verglichen: Maligne Melanome, benigne Läsionen, tumorfreie Kontrollgewebe und die Xiphophorus-Melanomzellinie (PSM). MSH2 und p53 wurden in allen untersuchten Geweben auf gleichem Niveau exprimiert. Die vergleichende Expressionsanalyse des vermeintlichen "melanoma susceptibility gene" cdkn2a im Melanom-Modell und der PSM-Zellinie bestätigte die bereits vorbeschriebene Überexpression des Zellzyklusinhibitors in malignen Melanomen von Xiphophorus-Hybriden. Die Untersuchung des Expressionsmusters von Rb in den oben genannten Geweben ergab eine verminderte Transkription dieses Gens in malignen Melanomen. Eine mögliche Interpretation dieses Ergebnisses wäre, einen Defekt in Rb oder pRB zu Grunde zu legen und die Hochregulation von cdkn2a entsprechend einer negativen Rückkopplungsschleife als physiologische Konsequenz anzusehen.
Das fakultativ intrazelluläre Bakterium Listeria monocytogenes besitzt die Fähigkeit, eukaryotische Wirtszellen zu penetrieren, sich in diesen zu vermehren, fortzubewegen und zwischen den Zellen auszubreiten. Im Zuge des intrazellulären Lebenszyklus gehen Listerien Wechselwirkungen mit ver-schiedenen zellulären Proteinen ein. Als eines dieser Proteine konnte das zelluläre Phosphoprotein Stathmin identifiziert werden. Dieses Protein bindet an Untereinheiten des Tubulins und destabilisiert dadurch Mikrotubuli (MT). Es wird durch Phosphorylierung von vier spezifischen Serinresten in seiner MT-destabilisierenden Aktivität reguliert. Da Stathmin als Antwort auf externe Signale zelluläre Funktionen, z. B. Zell-Proliferation und Differenzierung reguliert, vermutet man seine Funktion in einer Art Relais welches verschiedene Signale aus dem Umfeld der Zelle integriert. In mit L. monocytogenes infizierten Wirtszellen wird Stathmin an die Oberfläche intrazellulärer Bakterien rekrutiert. Inwiefern diese Rekrutierung das Phosphorylierungsmuster von Stathmin und damit dessen Aktivität beeinflusst, konnte im Rahmen dieser Arbeit nicht geklärt werden. Stathmin knock-out Mäuse sollten sich gut eignen, um die Rolle von Stathmin während einer Infektion mit L. monocytogenes EGD in vitro und in vivo zu untersuchen. Es stellte sich heraus, dass in Stathmin(-/-)-Makrophagen der intrazelluläre Lebenszyklus der Listerien nicht signifikant beeinflusst ist. Nach intravenöser Verabreichung von 5x103 L. monocytogenes waren drei Tage nach der Infektion in Leber und Milz der knock-out Mäuse allerdings signifikant mehr Listerien nachzuweisen, als in den Organen wildtypischer Mäuse. Mittels Immunfluoreszenzmikroskopie und einem anti-Stathmin-Antiersum konnte an mit verschiedenen L. monocytogenes-Mutanten infizierten Zellen gezeigt werden, dass Stathmin mit der Oberfläche intrazellulärer Listerien kolokalisiert. Allerdings konnten dabei die Angaben in der Literatur nicht bestätigt werden, wonach für diese Kolokalisation die Expression von ActA notwendig ist. Die Ergebnisse dieser Arbeit sprechen im Gegensatz zu den publizierten Daten dafür, dass Stathmin über einen bisher noch unbekannten Mechanismus ActA-unabhängig an intrazelluläre Listerien rekrutiert wird. Zweikomponentensysteme ermöglichen Bakterien eine rasche Anpassung an sich verändernde Umweltbedingungen, da sie extra- und intrazelluläre Stimuli in zelluläre Signale umwandeln. Um die 16 in der Genomsequenz von L. mono-cytogenes EGDe identifizierten Zweikomponentensysteme charakterisieren zu können, wurden individuelle Mutanten konstruiert, in denen individuelle Response Regulatorgene deletiert sind. Die erhaltenen Mutanten wurden in vitro und in vivo auf ihr Wachstumsverhalten hin untersucht. Es zeigte sich, dass unter den angewandten Kultur- und Versuchsbedingungen keines der Zweikomponentensysteme eine signifikante Rolle bei der Anpassung an Temperatur, sowie an oxidativen oder osmotischen Stress spielt. Die Zugabe von 5 % Ethanol hatte einen stark hemmenden Effekt auf das Wachstum von 4 Mutanten, wohingegen zwei andere Mutanten in Gegenwart des Alkohols deutlich besser wuchsen. Unter anaeroben Bedingungen konnte kein Unterschied im Wachstum beobachtet werden. Die Expression wichtiger Virulenzgene war in keiner der untersuchten Mutanten im Vergleich zum Ausgangsstamm verändert. Die intrazelluläre Replikation sowie intrazelluläre Bewegung und Ausbreitung im Zellrasen waren durch die Deletion der Response Regulatorgene nicht beeinträchtigt. Abgesehen von geringen Unterschieden in der Invasivität einiger Deletionsmutanten für Cos-1 und Caco-2 Zellen zeigte sich keiner der Response Regulatoren für den intrazellulären Lebenszyklus von L. monocytogenes erforderlich. Es zeigte sich, dass der in der vorliegenden Arbeit verwendete L. monocyto-genes-Wildstamm auch bei der für die Flagellenexpression normalerweise nicht-permissiven Temperatur von 37° C noch beweglich ist. Die L. monocytogenes ΔdegU-Mutante war dagegen auf Weichagar temperaturunabhängig unbeweglich. Die elektronenmikroskopische Analyse ergab, dass dieser Stamm im Gegensatz zum Wildtyp auch bei 24° C keine Flagellen ausbildet. Durch vergleichende Proteomanalysen konnte gezeigt werden, dass L. monocytogenes ΔdegU bei 24° C wesentliche Proteine des Flagellenapparates nicht synthetisiert. Mittels Transkriptomanalysen konnten die Ergebnisse der Proteomanalysen bestätigt werden. Es wurden neben Genen, die für Proteine der Flagellenbiosynthese und Chemotaxis codieren, noch weitere Gene identifiziert, die offensichtlich unter der transkriptionellen Kontrolle des Response Regulators DegU stehen. Die Ergebnisse der in vivo Studien zeigten, dass L. monocytogenes ΔdegU deutlich virulenzattenuiert ist. Für die restlichen L. monocytogenes ΔTCS-Mutanten waren im Vergleich zum Wildtyp die Unterschiede in Leber und Milz nur leicht verändert und statistisch nicht signifikant.
Die Histidin-Kinase BvgS des BvgAS-Zwei-Komponentensystems gehört zu den unorthodoxen Histidin-Kinasen, die im Gegensatz zu den klassischen Sensorkinasen durch eine komplexere Domänen-Struktur gekennzeichnet ist. Schon seit längerem ist bekannt, dass BvgS durch niedrige Temperaturen oder die Anwesenheit von chemischen Substanzen, wie Sulfationen oder Nikotinsäure inaktiviert wird. Zudem konnte in vitro gezeigt werden, dass die Autophosphorylierungs-Aktivität der BvgS Histidin-Kinase nach Inkubation mit oxidiertem Ubichinon inhibiert wird (Bock & Gross, 2002). Bislang ist weitgehend unklar, welche Bedeutung die zusätzlichen Domänen, wie die periplasmatische-, PAS- bzw. HPt-Domäne für die Signalwahrnehmung besitzen. Im Rahmen dieser Arbeit wurde deshalb nach Erstellung einer B. bronchiseptica spezifischen Genbank mit Hilfe des GAL4-Yeast Two-Hybrid (YTH) Systems nach Interaktionspartnern der einzelnen BvgS-Domänen gesucht. Nach dem Ausschluss von falsch-positiven Klonen und dem Durchlauf entsprechender Kontrollen konnten im YTH-System für die periplasmatische und die PAS-Domäne von BvgS insgesamt vier Interaktionspartner identifiziert werden. Für die HPt-Domäne konnte mit Hilfe des YTH-Systems kein möglicher Interaktionspartner gefunden werden. Als ein putativer Interaktionspartner der BvgS-PAS-Domäne wurde das BB0602-Protein identifiziert, das ein ATP-Bindeprotein darstellt, welches als Bestandteil eines ABC-Transport-System für den Transport von verzweigten Aminosäuren verantwortlich gemacht wird. Diese Interaktion konnte mittels eines GST-Pulldownassays bestätigt werden. Der biochemische Nachweis der übrigen identifizierten Protein-Interaktionen konnte im Rahmen dieser Arbeit nicht erbracht werden. Die Ergebnisse des YTH-Screenings deuten darauf hin, dass die Aktivität der BvgS Histidin-Kinase und damit die Virulenzgenexpression durch die An- bzw. Abwesenheit von verzweigten Aminosäuren beeinflusst werden könnte. Im Rahmen dieser Arbeit konnte die Relevanz der Interaktion zwischen der PAS-Domäne und dem ATP-Bindeprotein BB0602 nicht näher charakterisiert werden, so dass in Zukunft unter anderem die Konstruktion einer B. bronschiseptica bb0602-Deletionsmutante geplant ist, um somit mögliche Auswirkungen auf die Expression von bvg-abhängigen Genen zu beobachten. Ein weiteres Ziel dieser Arbeit lag in der Struktur-Funktionsanalyse des Response Regulators BvgA aus B. holmesii (BvgABH). Kürzlich konnte gezeigt werden, dass trotz der umfangreichen Sequenzkonservierung der BvgA-Proteine aus B. holmesii und B. pertussis, eine B. pertussis bvgA-Mutante nicht durch den bvgA-Lokus aus B. holmesii komplementiert werden konnte (Gerlach et al., 2004). Im Rahmen dieser Arbeit wurde ein hybrider Response Regulator BvgAfus konstruiert, der aus der Receiver- und Linker-Domäne des BvgABH-Proteins und der Output-Domäne von BvgABP zusammengesetzt ist. Voraussetzung hierfür war die Kenntnis der einzelnen Domänengrenzen und die Sequenz des Linker-Bereiches des Response Regulators BvgA aus B. pertussis (BvgABP), welche durch limitierte Proteolyse und massenspektrometrische Methoden identifiziert wurden (Bantscheff et al., 2000). Im Falle des hybriden Proteins konnte im Gegensatz zu BvgABH eine Bindung an BvgABP-abhängige Promotorsequenzen beobachtet werden. Zudem war BvgAfus in der Lage, die Expression BvgABP-abhängiger Gene in vivo zu induzieren. Allerdings war es in seiner Phosphorylierungseffizienz im Vergleich zum wildtypischen Response Regulator-Protein aus B. holmesii eingeschränkt. Die Ergebnisse deuten darauf hin, dass die wenigen Abweichungen zwischen den Aminosäuresequenzen der Output-Domänen dafür verantwortlich sind, dass das BvgABH-Protein die Funktion von BvgABP in vivo und in vitro nicht übernehmen kann. So unterscheiden sich die Output-Domänen der Response Regulatoren aus B. pertussis und B. holmesii in zehn Aminosäureaustauschen, wobei davon vier Aminosäuren innerhalb des Helix-Turn-Helix-Motives verändert sind. Um zu untersuchen, ob die unterschiedlichen DNA-Binde- und transkriptionsaktivierenden Eigenschaften von BvgABH im Besonderen auf diese Aminosäureunterschiede zurückzuführen sind, wurden mittels ortspezifischer Mutagenese die Aminosäuresequenz innerhalb des Helix-Turn-Helix-Motives an die Sequenz aus B. pertussis angeglichen. Das resultierende Protein BvgABH* zeigte eine dem wildtypischen BvgABH-Protein ähnliche Phosphorylierungseffizienz, war aber nicht in der Lage, BvgABP-abhängige Zielsequenzen spezifisch zu erkennen bzw. die Funktion des BvgABP-Proteins in vivo zu ersetzen. Dieses Ergebnis lässt vermuten, dass die wenigen Aminosäureunterschiede der Output-Domäne außerhalb der DNA-Binderegion zwar nicht im Zusammenhang mit der Phosphorylierungseffizienz stehen, jedoch die DNA-Bindeeigenschaften beeinflussen.
The desert isopod, Hemilepistus reaumuri, extremely common in the arid regions of North Africa and Asia Minor, depends upon the burrows it itself digs for survival during the hotter parts of the year. The dig-ging of new burrows is limited by chmatic conditions to a short period during the spring. Burrows must be constantly defendet - especially against roving eonspecifics. The decisive problem of a connnuous burrow defense is solved through cooperative behavior: the adult woodlice form monogamous pairs whose partners recognize one another individually. Here, questions on the binding of partners, especially the problem of the binding of male to female will be treated upon, along with questions on the evolution of monogamy, wherein the purely maternal families of Porcellio species will be taken as models for intermediäre stages. At first, males olHemilepistus are not permitted to copulate at all; later, for a relatively long period, they are only permitted incomplete copulations, the females alone have control over the partunal ecdysis; they alone determine the moment of final copulations. Under the thermal conditions prevalent during the season of pair formation, a female irreversibly induces a parturial ecdysis only when it has spent a minimum of sev-eral days in her own burrow with a specific male. At higher average temperatures, the number of females which undergo parturial ecdyses without these preconditions increases sharply. Males cannot greatly lnrlu-ence the willingness of females to reproduce with the investment they make in the digging of burrows; the factors deciding this are the male's presence and its role as guard. The first condition necessary for the genesis of monogamy might have been the evolution of a stncüy lo-cation-dependent copulatory behavior, which guaranteed the male exclusive mating pnveliges with the female whose location - the burrow - he acheived control of. A male must, under these conditions, serve guard duty in his own interest, and defend the burrow against competitors (Cf or 2) seeking an already-dug burrow. The decisive advantage for the female in the beginning of the development was probably that she could leave the burrow for extended feeding excursions, whereas alone it would have to either completely forego nourishment or, as is the case with the Porcellio species mentioned, must greatly restrict the spectrum of food that it can use (to that which is to be found only a short distance from the burrow and which can eas-ily be carried inside the burrow). This could be a disadvantage, especially during egg production. Necessary to the male's successful defense of the burrow is that he recognises his female. Studies of the Canary Island Porcellio species have shown over which pathways and under what selection pressures the recopinon of individuals, as is realized mHemilepistus, could have evolved. Females can bind males longer, the longer the period of their attraction is extended: Females olHemilepistus reaumuri have been proven to be al·ready att-ractive before they are ready to copulate and still remain attractive after they have copulated. The conse-quences of the last fact will be discussed. The question of why the males remain with the females after the parturial ecdysis will also be discussed: The great danger to the male's investment resulting from a tooi early abandoning, and the low probability of successfully finding another partner after a later abandomng should prevent a positive balance in the males' cost-effecriveness calculations.
Introduction The fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of suspicion of overdose, when patients switch from existing oral anticoagulant, in patients with hepatic or renal impairment, by concomitant use of interaction drugs, or to assess anticoagulant concentration in patients' blood before major surgery. Methods Here, we describe a quick and precise method to measure the coagulation inhibitors dabigatran and rivaroxaban using ultra-performance liquid chromatography electrospray ionization-tandem mass spectrometry in multiple reactions monitoring (MRM) mode (UPLC-MRM MS). Internal standards (ISs) were added to the sample and after protein precipitation; the sample was separated on a reverse phase column. After ionization of the analytes the ions were detected using electrospray ionization-tandem mass spectrometry. Run time was 2.5 minutes per injection. Ion suppression was characterized by means of post-column infusion. Results The calibration curves of dabigatran and rivaroxaban were linear over the working range between 0.8 and 800 mu g/L (r > 0.99). Limits of detection (LOD) in the plasma matrix were 0.21 mu g/L for dabigatran and 0.34 mu g/L for rivaroxaban, and lower limits of quantification (LLOQ) in the plasma matrix were 0.46 mu g/L for dabigatran and 0.54 mu g/L for rivaroxaban. The intraassay coefficients of variation (CVs) for dabigatran and rivaroxaban were < 4% and 6%; respectively, the interassay CVs were < 6% for dabigatran and < 9% for rivaroxaban. Inaccuracy was < 5% for both substances. The mean recovery was 104.5% (range 83.8-113.0%) for dabigatran and 87.0%(range 73.6-105.4%) for rivaroxaban. No significant ion suppressions were detected at the elution times of dabigatran or rivaroxaban. Both coagulation inhibitors were stable in citrate plasma at -20 degrees C, 4 degrees C and even at RT for at least one week. A method comparison between our UPLC-MRM MS method, the commercially available automated Direct Thrombin Inhibitor assay (DTI assay) for dabigatran measurement from CoaChrom Diagnostica, as well as the automated anti-Xa assay for rivaroxaban measurement from Chromogenix both performed by ACL-TOP showed a high degree of correlation. However, UPLC-MRM MS measurement of dabigatran and rivaroxaban has a much better selectivity than classical functional assays measuring activities of various coagulation factors which are susceptible to interference by other coagulant drugs. Conclusions Overall, we developed and validated a sensitive and specific UPLC-MRM MS assay for the quick and specific measurement of dabigatran and rivaroxaban in human plasma.
Increasing human land use for agriculture and housing leads to the loss of natural habitat and to widespread declines in wild bees. Bee foraging dynamics and fitness depend on the availability of resources in the surrounding landscape, but how precisely landscape related resource differences affect bee foraging patterns remains unclear. To investigate how landscape and its interaction with season and weather drive foraging and resource intake in social bees, we experimentally compared foraging activity, the allocation of foragers to different resources (pollen, nectar, and resin) and overall resource intake in the Australian stingless bee Tetragonula carbonaria (Apidae, Meliponini). Bee colonies were monitored in different seasons over two years. We compared foraging patterns and resource intake between the bees' natural habitat (forests) and two landscapes differently altered by humans (suburban gardens and agricultural macadamia plantations). We found foraging activity as well as pollen and nectar forager numbers to be highest in suburban gardens, intermediate in forests and low in plantations. Foraging patterns further differed between seasons, but seasonal variations strongly differed between landscapes. Sugar and pollen intake was low in plantations, but contrary with our predictions, it was even higher in gardens than in forests. In contrast, resin intake was similar across landscapes. Consequently, differences in resource availability between natural and altered landscapes strongly affect foraging patterns and thus resource intake in social bees. While agricultural monocultures largely reduce foraging success, suburban gardens can increase resource intake well above rates found in natural habitats of bees, indicating that human activities can both decrease and increase the availability of resources in a landscape and thus reduce or enhance bee fitness.
Tumor-induced angiogenesis is of major interest for oncology research. Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor characterized so far. VEGF blockade was shown to be sufficient for angiogenesis inhibition and subsequent tumor regression in several preclinical tumor models. Bevacizumab was the first treatment targeting specifically tumor-induced angiogenesis through VEGF blockade to be approved by the Food and Drugs Administration (FDA) for cancer treatment. However, after very promising results in preclinical evaluations, VEGF blockade did not show the expected success in patients. Some tumors became resistant to VEGF blockade. Several factors have been accounted responsible, the over-expression of other angiogenic factors, the noxious influence of VEFG blockade on normal tissues, the selection of hypoxia resistant neoplastic cells, the recruitment of hematopoietic progenitor cells and finally the transient nature of angiogenesis inhibition by VEGF blockade. The development of blocking agents against other angiogenic factors like placental growth factor (PlGF) and Angiopoietin-2 (Ang-2) allows the development of an anti-angiogenesis strategy adapted to the profile of the tumor.
Oncolytic virotherapy uses the natural propensity of viruses to colonize tumors to treat cancer. The recombinant vaccinia virus GLV-1h68 was shown to infect, colonize and lyse several tumor types. Its descendant GLV-1h108, expressing an anti-VEGF antibody, was proved in previous studies to inhibit efficiently tumor induced angiogenesis. Additional VACVs expressing single chain antibodies (scAb) antibodies against PlGF and Ang-2 alone or in combination with anti VEGF scAb were designed.
In this study, VACV-mediated anti-angiogenesis treatments have been evaluated in several preclinical tumor models. The efficiency of PlGF blockade, alone or in combination with VEGF, mediated by VACV has been established and confirmed. PlGF inhibition alone or with VEGF reduced tumor burden 5- and 2-folds more efficiently than the control virus, respectively.
Ang-2 blockade efficiency for cancer treatment gave controversial results when tested in different laboratories. Here we demonstrated that unlike VEGF, the success of Ang-2 blockade is not only correlated to the strength of the blockade. A particular balance between Ang-2, VEGF and Ang-1 needs to be induced by the treatment to see a regression of the tumor and an improved survival. We saw that Ang-2 inhibition delayed tumor growth up to 3-folds compared to the control virus. These same viruses induced statistically significant tumor growth delays. This study unveiled the need to establish an angiogenic profile of the tumor to be treated as well as the necessity to better understand the synergic effects of VEGF and Ang-2. In addition angiogenesis inhibition by VACV-mediated PlGF and Ang-2 blockade was able to reduce the number of metastases and migrating tumor cells (even more efficiently than VEGF blockade).
VACV colonization of tumor cells, in vitro, was limited by VEGF, when the use of the anti-VEGF VACV GLV-1h108 drastically improved the colonization efficiency up to 2-fold, 72 hours post-infection. These in vitro data were confirmed by in vivo analysis of tumors. Fourteen days post-treatment, the anti-VEGF virus GLV-1h108 was colonizing 78.8% of the tumors when GLV-1h68 colonization rate was 49.6%. These data confirmed the synergistic effect of VEGF blockade and VACV replication for tumor regression.
Three of the tumor cell lines used to assess VACV-mediated angiogenesis inhibition were found, in certain conditions, to mimic either endothelial cell or pericyte functions, and participate directly to the vascular structure. The expression by these tumor cells of e-selectin, p-selectin, ICAM-1 and VCAM-1, normally expressed on activated endothelial cells, corroborates our findings. These proteins play an important role in immune cell recruitment, and there amount vary in presence of VEGF, PlGF and Ang-2, confirming the involvement of angiogenic factors in the immuno-modulatory abilities of tumors.
In this study VACV-mediated angiogenesis blockade proved its potential as a therapeutic agent able to treat different tumor types and prevent resistance observed during bevacizumab treatment by acting on different factors. First, the expression of several antibodies by VACV would prevent another angiogenic factor to take over VEGF and stimulate angiogenesis. Then, the ability of VACV to infect tumor cells would prevent them to form blood vessel-like structures to sustain tumor growth, and the localized delivery of the antibody would decrease the risk of adverse effects. Next, the blockade of angiogenic factors would improve VACV replication and decrease the immune-modulatory effect of tumors. Finally the fact that angiogenesis blockade lasts until total regression of the tumor would prevent the recovery of the tumor-associated vasculature and the relapse of patients.
Using Expansion Microscopy to Visualize and Characterize the Morphology of Mitochondrial Cristae
(2020)
Mitochondria are double membrane bound organelles indispensable for biological processes such as apoptosis, cell signaling, and the production of many important metabolites, which includes ATP that is generated during the process known as oxidative phosphorylation (OXPHOS). The inner membrane contains folds called cristae, which increase the membrane surface and thus the amount of membrane-bound proteins necessary for the OXPHOS. These folds have been of great interest not only because of their importance for energy conversion, but also because changes in morphology have been linked to a broad range of diseases from cancer, diabetes, neurodegenerative diseases, to aging and infection. With a distance between opposing cristae membranes often below 100 nm, conventional fluorescence imaging cannot provide a resolution sufficient for resolving these structures. For this reason, various highly specialized super-resolution methods including dSTORM, PALM, STED, and SIM have been applied for cristae visualization. Expansion Microscopy (ExM) offers the possibility to perform super-resolution microscopy on conventional confocal microscopes by embedding the sample into a swellable hydrogel that is isotropically expanded by a factor of 4–4.5, improving the resolution to 60–70 nm on conventional confocal microscopes, which can be further increased to ∼ 30 nm laterally using SIM. Here, we demonstrate that the expression of the mitochondrial creatine kinase MtCK linked to marker protein GFP (MtCK-GFP), which localizes to the space between the outer and the inner mitochondrial membrane, can be used as a cristae marker. Applying ExM on mitochondria labeled with this construct enables visualization of morphological changes of cristae and localization studies of mitochondrial proteins relative to cristae without the need for specialized setups. For the first time we present the combination of specific mitochondrial intermembrane space labeling and ExM as a tool for studying internal structure of mitochondria.
Oncogenic transformation of lung epithelial cells is a multistep process, frequently starting with the inactivation of tumour suppressors and subsequent development of activating mutations in proto-oncogenes, such as members of the PI3K or MAPK families. Cells undergoing transformation have to adjust to changes, including altered metabolic requirements. This is achieved, in part, by modulating the protein abundance of transcription factors. Here, we report that the ubiquitin carboxyl-terminal hydrolase 28 (USP28) enables oncogenic reprogramming by regulating the protein abundance of proto-oncogenes such as c-JUN, c-MYC, NOTCH and ∆NP63 at early stages of malignant transformation. USP28 levels are increased in cancer compared with in normal cells due to a feed-forward loop, driven by increased amounts of oncogenic transcription factors such as c-MYC and c-JUN. Irrespective of oncogenic driver, interference with USP28 abundance or activity suppresses growth and survival of transformed lung cells. Furthermore, inhibition of USP28 via a small-molecule inhibitor resets the proteome of transformed cells towards a ‘premalignant’ state, and its inhibition synergizes with clinically established compounds used to target EGFR\(^{L858R}\)-, BRAF\(^{V600E}\)- or PI3K\(^{H1047R}\)-driven tumour cells. Targeting USP28 protein abundance at an early stage via inhibition of its activity is therefore a feasible strategy for the treatment of early-stage lung tumours, and the observed synergism with current standard-of-care inhibitors holds the potential for improved targeting of established tumours.
∆Np63 is a master regulator of squamous cell identity and regulates several signaling pathways that crucially
contribute to the development of squamous cell carcinoma (SCC) tumors. Its contribution to coordinating the
expression of genes involved in oncogenesis, epithelial identity, DNA repair, and genome stability has been
extensively studied and characterized. For SCC, the expression of ∆Np63 is an essential requirement to
maintain the malignant phenotype. Additionally, ∆Np63 functionally contributes to the development of cancer
resistance toward therapies inducing DNA damage.
SCC patients are currently treated with the same conventional Cisplatin therapy as they would have been
treated 30 years ago. In contrast to patients with other tumor entities, the survival of SCC patients is limited,
and the efficacy of the current therapies is rather low. Considering the rising incidences of these tumor entities,
the development of novel SCC therapies is urgently required. Targeting ∆Np63, the transcription factor, is a
potential alternative to improve the therapeutic response and clinical outcomes of SCC patients.
However, ∆Np63 is considered “undruggable.” As is commonly observed in transcription factors, ∆Np63 does
not provide any suitable domains for the binding of small molecule inhibitors. ∆Np63 regulates a plethora of
different pathways and cellular processes, making it difficult to counteract its function by targeting
downstream effectors. As ∆Np63 is strongly regulated by the ubiquitin–proteasome system (UPS), the
development of deubiquitinating enzyme inhibitors has emerged as a promising therapeutic strategy to target
∆Np63 in SCC treatment.
This work involved identifying the first deubiquitinating enzyme that regulates ∆Np63 protein stability. Stateof-the-art SCC models were used to prove that USP28 deubiquitinates ∆Np63, regulates its protein stability,
and affects squamous transcriptional profiles in vivo and ex vivo. Accordingly, SCC depends on USP28 to
maintain essential levels of ∆Np63 protein abundance in tumor formation and maintenance. For the first time,
∆Np63, the transcription factor, was targeted in vivo using a small molecule inhibitor targeting the activity of
USP28. The pharmacological inhibition of USP28 was sufficient to hinder the growth of SCC tumors in
preclinical mouse models.
Finally, this work demonstrated that the combination of Cisplatin with USP28 inhibitors as a novel therapeutic
alternative could expand the limited available portfolio of SCC therapeutics. Collectively, the data presented
within this dissertation demonstrates that the inhibition of USP28 in SCC decreases ∆Np63 protein abundance,
thus downregulating the Fanconi anemia (FA) pathway and recombinational DNA repair. Accordingly, USP28
inhibition reduces the DNA damage response, thereby sensitizing SCC tumors to DNA damage therapies, such
as Cisplatin.
Squamous cell carcinomas are therapeutically challenging tumor entities. Low response rates to radiotherapy and chemotherapy are commonly observed in squamous patients and, accordingly, the mortality rate is relatively high compared to other tumor entities. Recently, targeting USP28 has been emerged as a potential alternative to improve the therapeutic response and clinical outcomes of squamous patients. USP28 is a catalytically active deubiquitinase that governs a plethora of biological processes, including cellular proliferation, DNA damage repair, apoptosis and oncogenesis. In squamous cell carcinoma, USP28 is strongly expressed and stabilizes the essential squamous transcription factor ΔNp63, together with important oncogenic factors, such as NOTCH1, c-MYC and c-JUN. It is presumed that USP28 is an oncoprotein; however, recent data suggest that the deubiquitinase also has an antineoplastic effect regulating important tumor suppressor proteins, such as p53 and CHK2. In this review, we discuss: (1) The emerging role of USP28 in cancer. (2) The complexity and mutational landscape of squamous tumors. (3) The genetic alterations and cellular pathways that determine the function of USP28 in squamous cancer. (4) The development and current state of novel USP28 inhibitors.
Multiple myeloma (MM) represents a haematological cancer characterized by the pathological hyper proliferation of antibody-producing B-lymphocytes. Patients typically suffer from kidney malfunction and skeletal disorders. In the context of MM, the transforming growth factor β (TGFβ) member Activin A was recently identified as a promoter of both accompanying symptoms. Because studies have shown that bone morphogenetic protein (BMP)-2-mediated activities are counteracted by Activin A, we analysed whether BMP2, which also binds to the Activin A receptors ActRII and ActRIIB but activates the alternative SMAD-1/5/8 pathway, can be used to antagonize Activin A activities, such as in the context of MM. Therefore three BMP2 derivatives were generated with modified binding activities for the type II (ActRIIB) and/or type I receptor (BMPRIA) showing either increased or decreased BMP2 activity. In the context of MM these BMP2 muteins show two functionalities since they act as a) an anti-proliferative/apoptotic agent against neoplastic B-cells, b) as a bone-formation promoting growth factor. The molecular basis of both activities was shown in two different cellular models to clearly rely on the properties of the investigated BMP2 muteins to compete for the binding of Activin A to the Activin type II receptors. The experimental outcome suggests new therapeutic strategies using BMP2 variants in the treatment of MM-related pathologies.
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a promising approach for cancer therapy. Recently, we showed that the oncolytic vaccinia virus GLV-1h68 has a therapeutic potential in treating human prostate and hepatocellular carcinomas in xenografted mice. In this study, we describe the use of dynamic boolean modeling for tumor growth prediction of vaccinia virus-injected human tumors. Antigen profiling data of vaccinia virus GLV-1h68-injected human xenografted mice were obtained, analyzed and used to calculate differences in the tumor growth signaling network by tumor type and gender. Our model combines networks for apoptosis, MAPK, p53, WNT, Hedgehog, the T-killer cell mediated cell death, Interferon and Interleukin signaling networks. The in silico findings conform very well with in vivo findings of tumor growth. Similar to a previously published analysis of vaccinia virus-injected canine tumors, we were able to confirm the suitability of our boolean modeling for prediction of human tumor growth after virus infection in the current study as well. In summary, these findings indicate that our boolean models could be a useful tool for testing of the efficacy of VACV-mediated cancer therapy already before its use in human patients.
Cancer-related anemia is prevalent in cancer patients. Anemia negatively affects normal mental and physical function capacity with common symptoms s like fatigue, headache, or depression. Human erythropoietin (hEPO), a glycoprotein hormone regulating red blood cell formation, is approved for the treatment of cancer-related anemia. It has shown benefits in correcting anemia, and subsequently improving health-related quality of life and/or enhancing radio-, and chemotherapy. Several recent clinical trials have suggested that recombinant hEPO (rhEPO) may promote tumor growth that raises the questions concerning the safety of using rhEPO for cancer treatment. However in others, such effects were not indicated. As of today, the direct functional effect of rhEPO in tumor models remains controversial and needs to be further analyzed. Based on the GLV-1h68 backbone, the hEPO-expressing recombinant VACV strains (EPO-VACVs) GLV-1h210, GLV-1h211, GLV-1h212 and GLV-1h213 were generated by replacing the lacZ expression cassette at the J2R locus with hEPO under the control of different vaccinia promoters p7.5, pSE, pSEL, pSL, respectively. Also, GLV-1h209 was generated, which is similar to GLV-1h210 but expresses a mutated non-functinal EPO (R103A). The EPO-VACV strains were characterized for their oncolytic efficacy in lung (A549) cancer cells in culture and tumor xenografts. Concomitantly, the effects of locally expressed hEPO in tumors on virus replication, host immune infiltration, tumor vascularization and tumor growth were also evaluated. As expected, EPO-VACVs enhanced red blood cell (RBC) formation in xenograft model. The number of RBCs and hemoglobin (Hb) levels were significantly increased in EPO-VACVs-treated mice compared to GLV-1h68-treated or untreated control mice. However, the mean size of RBC or Hb content per RBC remained normal. Furthermore, over-expression of hEPO did not significantly affect numbers of lymphocytes, monocytes, leucocytes or platelets in the peripheral blood stream. The expression of hEPO in colonized tumors of mice treated with EPO-VACVs was demonstrated by immunohistological staining. Interestingly, there were 9 - 10 hEPO isoforms detected either in tumors, cells, or supernatant, while 3-4 basic isoforms were missing in blood serum, where only six hEPO isoforms were found. Tumor-bearing mice after treatment with EPO-VACVs showed enhanced tumor regression compared to GLV-1h68. The virus titers in tumors in EPO-VACVs-treated mice were 3-4 fold higher compared to GLV-1h68-treated mice. Nevertheless, no significant difference in virus titers among EPO-VACVs was found. The blood vessels in tumors were significantly enlarged while the blood vessel density remained unchanged compared to the GLV-1h68 treated mice, indicating that hEPO did not affect endothelial cell proliferation in this model. Meanwhile, rhEPO (Epoetin alfa) alone or in combination with GLV-1h68 did not show any signs of enhanced tumor growth when compared to untreated controls and GLV-1h68 groups, while doses used were clinical relevant (500 U/kg). These findings suggested that hEPO did not promote angiogenesis or tumor growth in the A549 tumor xenograft model. Human EPO has been reported to function as an immune modulator. In this study, however, we did not find any involvement of hEPO in immune cytokine and chemokine expression or innate immune cell infiltration (leucocytes, B cells, macrophages and dendritic cells) into infected tumors. The degree of immune infiltration and cytokine expression was directly correlated to the number of virus particles. Increased virus replication, led to more recruited immune cells and secreted cytokines/chemokines. It was proposed that tumor regression was at least partially mediated through activation of innate immune mechanisms. In conclusion, the novel EPO-VACVs were shown to significantly increase the number of RBCs, Hb levels, and virus replication in tumors as well as to enhance tumor regression in the A549 tumor xenograft model. Moreover, locally expressed hEPO did not promote tumor angiogenesis, tumor growth, and immune infiltration but was shown to causing enlarged tumoral microvessels which facilitated virus spreading. It is conceivable that in a possible clinical application, anemic cancer patients could benefit from the EPO-VACVs, where they could serve as “wellness pills” to decrease anemic symptoms, while simultaneously destroying tumors.
Oncolytic virotherapy represents a promising approach to revolutionize cancer therapy. Several preclinical and clinical trials display the safety of oncolytic viruses as wells as their efficiency against solid tumors. The development of complementary diagnosis and monitoring concepts as well as the optimization of anti-tumor activity are key points of current virotherapy research. Within the framework of this thesis, the diagnostic and therapeutic prospects of beta-glucuronidase expressed by the oncolytic vaccinia virus strain GLV-1h68 were evaluated. In this regard, a beta-glucuronidase-based, therapy-accompanying biomarker test was established which is currently under clinical validation. By using fluorescent substrates, the activity of virally expressed beta-glucuronidase could be detected and quantified. Thereby conclusions about the replication kinetics of oncolytic viruses in animal models and virus-induced cancer cell lysis could be drawn. These findings finally led to the elaboration and establishment of a versatile biomarker assay which allows statements regarding the replication of oncolytic viruses in mice based on serum samples. Besides the analysis of retrospective conditions, this test is able to serve as therapy-accompanying monitoring tool for virotherapy approaches with beta-glucuronidase-expressing viruses. The newly developed assay also served as complement to routinely used plaque assays as well as reference for virally expressed anti-angiogenic antibodies in additional preclinical studies. Further validation of this biomarker test is currently taking place in the context of clinical trials with GL-ONC1 (clinical grade GLV-1h68) and has already shown promising preliminary results. It was furthermore demonstrated that fluorogenic substrates in combination with beta-glucuronidase expressed by oncolytic viruses facilitated the optical detection of solid tumors in preclinical models. In addition to diagnostic purposes, virus-encoded enzymes could also be combined with prodrugs resulting in an improved therapeutic outcome of oncolytic virotherapy. In further studies, the visualization of virus-induced immune reactions as well as the establishment of innovative concepts to improve the therapeutic outcome of oncolytic virotherapy could be accomplished. In conclusion, the results of this thesis provide crucial findings about the influence of virally expressed beta-glucuronidase on various diagnostic concepts in the context of oncolytic virotherapy. In addition, innovative monitoring and therapeutic strategies could be established. Our preclinical findings have important clinical influence, particularly by the development of a therapy-associated biomarker assay which is currently used in different clinical trials.
Vaccinia virus plays an important role in human medicine and molecular biology ever since the 18th century after E. Jenner discovered its value as a vaccination virus against smallpox. After the successful eradication of smallpox, vaccinia virus, apart from its use as a vaccine carrier, is today mainly used as a viral vector in molecular biology and increasingly in cancer therapy. The capability to specifically target and destroy cancer cells makes it a perfect agent for oncolytic virotherapy. Furthermore, the virus can easily be modified by inserting genes encoding therapeutic or diagnostic proteins to be expressed within the tumor. The emphasis in this study was the diagnosis of tumors using different vaccinia virus strains. Viruses with metal-accumulating capabilities for tumor detection via MRI technology were generated and tested for their usefulness in cell culture and in vivo. The virus strains GLV-1h131, GLV-1h132, and GLV-1h133 carry the gene encoding the two subunits of the iron storage protein ferritin under the control of three different promoters. GLV-1h110, GLV-1h111, and GLV-1h112 encode the bacterial iron storage protein bacterioferritin, whereas GLV-1h113 encodes the codon-optimized version of bacterioferritin for more efficient expression in human cells. GLV-1h22 contains the transferrin receptor gene, which plays an important role in iron uptake, and GLV-1h114 and GLV-1h115 contain the murine transferrin receptor gene. For possibly better iron uptake the virus strains GLV-1h154, GLV-1h155, GLV-1h156, and GLV-1h157 were generated, each with a version of a ferritin gene and a transferrin receptor gene. GLV-1h154 carries the genes that encode bacterioferritin and human transferrin receptor, GLV-1h155 the human ferritin H-chain gene and the human transferrin receptor gene. GLV-1h156 and GLV-1h157 infected cells both express the mouse transferrin receptor and bacterioferritin or human ferritin H-chain, respectively. The virus strains GLV-1h186 and GLV-1h187 were generated to contain a mutated form of the ferritin light chain, which was shown to result in iron overload and the wildtype light chain gene, respectively. The gene encoding the Divalent Metal Transporter 1, which is a major protein in the uptake of iron, was inserted in the virus strain GLV-1h102. The virus strain GLV-1h184 contains the magA gene of the magnetotactic bacterium Magnetospirillum magnetotacticum, which produces magnetic nanoparticles for orientation in the earth’s magnetic field. Initially the infection and replication capability of all the virus strains were analyzed and compared to that of the parental virus strain GLV-1h68, revealing that all the viruses were able to infect cells of the human cancer cell lines A549 and GI-101A. All constructs exhibited a course of infection comparable to that of GLV-1h68. Next, to investigate the expression of the foreign proteins in GI-101A and A549 cells with protein analytical methods, SDS-gelelectrophoresis, Western blots and ELISAs were performed. The proteins, which were expressed under the control of the strong promoters, could be detected using these methods. To be able to successfully detect the protein expression of MagA and DMT1, which were expressed under the control of the weak promoter, the more sensitive method RT-PCR was used to at least confirm the transcription of the inserted genes. The determination of the iron content in infected GI-101A and A549 cells showed that infection with all used virus strains led to iron accumulation in comparison to uninfected cells, even infection with the parental virus strain GLV-1h68. The synthetic phytochelatin EC20 was also shown to enhance the accumulation of different heavy metals in bacterial cultures. In vivo experiments with A549 tumor-bearing athymic nude mice revealed that 24 days post infection virus particles were found mainly in the tumor. The virus-mediated expression of recombinant proteins in the tumors was detected successfully by Western blot. Iron accumulation in tumor lysates was investigated by using the ferrozine assay and led to the result that GLV-1h68-infected tumors had the highest iron content. Histological stainings confirmed the finding that iron accumulation was not a direct result of the insertion of genes encoding iron-accumulating proteins in the virus genome. Furthermore virus-injected tumorous mice were analyzed using MRI technology. Two different measurements were performed, the first scan being done with a seven Tesla small animal scanner seven days post infection whereas the second scan was performed using a three Tesla human scanner 21 days after virus injection. Tumors of mice injected with the virus strains GLV-1h113 and GLV-1h184 were shown to exhibit shortened T2 and T2* relaxation times, which indicates enhanced iron accumulation. In conclusion, the experiments in this study suggest that the bacterioferritin-encoding virus strain GLV-1h113 and the magA-encoding virus strain GLV-1h184 are promising candidates to be used for cancer imaging after further analyzation and optimization.
Over the past 30 years, much effort and financial support have been invested in the fight against cancer, yet cancer still represents the leading cause of death in the world. Conventional therapies for treatment of cancer are predominantly directed against tumor cells. Recently however, new treatments options have paid more attention to exploiting the advantage of targeting the tumor stroma instead.
Vaccinia virus (VACV) has played an important role in human medicine since the 18th century as a vaccination against smallpox. In our laboratory, the recombinant, replication-competent vaccinia virus, GLV-1h68, was shown to enter, colonize and destroy cancer cells both in cell culture, and in vivo, in xenograft models (Zhang, Yu et al. 2007). In addition, combined therapy of GLV-1h68 and anti-VEGF immunotherapy significantly enhanced antitumor therapy in vivo (Frentzen, Yu et al. 2009).
In this study, we constructed several new recombinant VACVs carrying genes encoding different antibodies against fibroblast activation protein (FAP) in stroma (GLV-1h282), nanobody against the extracellular domain of epidermal growth factor receptor (EGFR, GLV-1h442) or antibodies targeting both vascular endothelial growth factor (VEGF) and EGFR (GLV-1h444) or targeting both VEGF and FAP (GLV-1h446).
The expression of the recombinant proteins was first verified using protein analytical methods, SDS-gel electrophoresis, Western blot analysis, immunoprecipitation (IP) assays and ELISA assays. The proteins were detected after infection of the cells with the different VACVs and the recombinant proteins purified by affinity adsorption. The purified antibodies were shown to specifically bind to their respective antigens.
Secondly, the infection and replication capability of all the virus strains was analyzed in cell culture using several human tumor cell lines (A549, FaDu or DU145), revealing that all the new recombinant VACVs were able to infect cancer cells with comparable efficiency to the parental viruses from which they were derived.
Thirdly, the antitumor efficacy of the new recombinant VACVs was evaluated in vivo using several human cancer xenograft models in mice. In A549 and DU145 xenografts, the new recombinant VACVs exhibited an enhanced therapeutic efficacy compared to GLV-1h68 with no change in toxicity in mice. In the FaDu xenograft, treatment with GLV-1h282 (anti-FAP) significantly slowed down the speed of tumor growth compared to GLV-1h68. Additionally, treatment with the recombinant VACVs expressed the various antibodies achieved comparable or superior therapeutic effects compared to treatment with a combination of GLV-1h68 and the commercial therapeutic antibodies, Avastin, Erbitux or both.
Next, the virus distribution in tumors and organs of treated mice was evaluated. For most of the viruses, the virus titer in tumors was not signficantly diffferent than GLV-1h68. However, for animals treated with GLV-1h282, the virus titer in tumors was significantly higher than with GLV-1h68. This may be the reason for enhanced antitumor efficacy of GLV-1h282 in vivo.
Lastly, the underlying mechanisms of therapeutic antibody-enhanced antitumor effects were investigated by immunohistochemistry. Blood vessels density and cell proliferation in tumors were suppressed after treatment with the antibody-encoded VACVs. The results indicated that the suppression of angiogenesis or cell proliferation in tumors may cause the observed therapeutic effect.
In conclusion, the results of the studies presented here support the hypothesis that the treatment of solid tumors with a combination of oncolytic virotherapy and immunotherapy has an additive effect over each treatment alone. Moreover, expression of the immunotherapeutic antibody by the oncolytic VACV locally in the tumor enhances the antitumor effect over systemic treatment with the same antibody. Combined, these results indicate that therapy with oncolytic VACVs expressing-therapeutic antibodies may be a promising approach for the treatment of cancer.